What Lactafem Treats: Main Uses and Benefits

Lactafem, an estrogen-free progestogen-only contraceptive, is commonly used to help with addressing symptoms that interfere with daily functioning in specific clinical situations. This medication plays a role in managing symptoms related to heightened physiological activity for women of childbearing potential.

The primary therapeutic applications involve conditions associated with acute or episodic changes and applied across domains where additional symptomatic support is needed. The use of this medicine may help patients cope more steadily with symptom fluctuations and distress related to conception risk, thereby supporting a more manageable experience of day-to-day stability in reproductive planning.

Contraception for Estrogen-Sensitive Patient Groups

This therapeutic domain is considered relevant in clinical settings where patients require additional symptomatic support due to the nature of the hormonal component. This is commonly used in patient groups who may have conditions where functional stability becomes affected by other hormonal component types. The medication contributes to improved comfort and supports the patient during difficult episodes, assisting with maintaining functional stability and general well-being during symptomatic phases related to estrogen sensitivity.

---

Quick Fact: Primary Therapeutic Context
Used for managing: symptoms that create noticeable physiological strain, and relevant in contexts marked by increased discomfort or tension.

Who Can and Cannot Use Lactafem?

The eligibility for using Lactafem (Desogestrel) is defined by regulatory authorities based on specific medical conditions and life stages. This medicine is primarily indicated for women of childbearing potential seeking contraception.

Absolute Prohibitions (Contraindications)

Lactafem must not be used by individuals with certain pre-existing conditions, as stated in official labeling:

• Active Venous Thromboembolic Disorder (e.g., deep vein thrombosis or pulmonary embolism).
• Severe Hepatic Disease (history or presence) until liver function values have normalized.
• Known or Suspected Sex-Steroid Sensitive Malignancies, such as breast cancer.
• Undiagnosed Vaginal Bleeding.

Eligibility by Age and Physiological State

Population Group	Eligibility Status (Regulatory)
Adolescents (< 18 years)	Safety and efficacy have not been established; use is not recommended.
Older Adults (Geriatric)	Generally not indicated for use.
Pregnancy	Not indicated; must be stopped if conception occurs.
Lactation/Breastfeeding	Can be used; does not negatively affect milk quality or production.

Eligibility is also conditional for those with a history of thrombo-embolic disorders, requiring careful assessment, and use should be considered for discontinuation during periods of long-term immobilisation.

Interactions with other medicines and products

Lactafem (desogestrel) is primarily susceptible to pharmacokinetic interactions that modify the plasma concentration of its active metabolite, etonogestrel. These interactions are driven by co-administered medicines that affect the metabolic enzymes responsible for its clearance.

Documented Interaction Categories

Interaction Type	Examples of Interacting Substances	Official Outcome Statement
Exposure Reduction (CYP Induction)	Anti-epileptics (e.g., Phenytoin, Carbamazepine), Antituberculosis drugs (e.g., Rifampicin), Herbal products (St. John's Wort)	Increased clearance and reduced systemic exposure of etonogestrel.
Exposure Increase (CYP Inhibition)	Antifungal agents (e.g., Itraconazole), Macrolide antibiotics (e.g., Clarithromycin)	Decreased clearance and potential increased exposure of etonogestrel.
Effect on Other Drugs	Ciclosporine, Lamotrigine	May increase plasma concentrations of Ciclosporine; may reduce plasma concentrations of Lamotrigine.

Co-administration is officially contraindicated with certain drug combinations used for Hepatitis C, specifically those containing ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, due to the documented risk of increased liver enzyme elevations. Patients with impaired hepatic function are noted in regulatory information as a specific population where the clearance of the steroid hormone may be altered, potentially affecting the outcome of these interactions.

Lactafem's action is fundamentally based on modulating signaling frequency within specific neural circuits by enhancing the brain's natural inhibitory system.

Modulating GABAergic Inhibition

Lactafem works by acting as a positive allosteric modulator (PAM) on GABAA receptors, the primary mediators of inhibition in the central nervous system (CNS). By binding to a specific site on the receptor, the drug increases the receptor's sensitivity to the natural inhibitory neurotransmitter GABA, amplifying the resulting influx of chloride ions (Cl^-) into the nerve cell . This core mechanism shifts the electrical potential toward inhibition, increasing the inhibitory effect on overall neuronal activity.

---

Decreasing Central Nervous System Excitability

The potentiation of GABAA signaling leads directly to a hyperpolarization of neurons, making them significantly less likely to fire action potentials and propagate signals. This mechanistic cascade is critical for decreasing the likelihood of action potential generation and modulating signaling frequency within motor control pathways. The physiological consequence of this central action is a decrease in skeletal muscle tone and a modulation of spinal reflex arc responses.

Instruction Map: How to use Lactafem — Official Administration Guidelines

---

Administration Scope

Route of administration: Oral.

Dosing schedule: One 75 mu g tablet is taken once daily.

Timing in relation to meals (if applicable): No specific requirement to take the tablet with or without food.

Preparation requirements (if applicable): None. Tablet is taken whole, with a small amount of liquid.

Age-group administration rules: The medicine is intended for use by women of childbearing potential. Official documents do not specify dose adjustments for older adults or for patients with renal or hepatic impairment.

Missed-dose rules: If the tablet is missed by less than 12 hours from the usual time, the dose must be taken immediately, and the next tablet taken at the usual time. If the tablet is missed by more than 12 hours (meaning more than 36 hours have elapsed between tablets), contraceptive protection may be reduced.

Special procedural conditions: The tablet must be taken every day at approximately the same time to maintain a consistent 24 hour dosing interval. Gastrointestinal upset, such as vomiting or severe diarrhea within 3 to 4 hours of intake, requires the same action as a missed dose.

---

Instruction Classifications (High-Level)

Administration method type (oral / IV / topical / inhaled / etc.): Oral.

Frequency pattern (daily / weekly / as-needed, etc.): Daily.

Regulatory basis (EMA / FDA / etc.): EMA / European National Agencies.

Use-context constraints: Continuous daily use with no interruption or break week between packs.

---

Resulting Procedural Structure

Official step sequence:

• Take one 75 mu g tablet orally every day.
• Start a new blister pack immediately the day after the previous one is finished, with no break.
• Adhere strictly to the 12 hour tolerance window for any delayed dose.

Connection to the overall use protocol (2–4 sentences): The official protocol mandates a fixed, 75mu g daily regimen of continuous oral use. This structure is designed to maintain consistent drug levels by requiring that the daily dose is taken at a highly regular time, ensuring the uninterrupted transition between blister packs. The entire use pattern is governed by a 12 hour procedural constraint on timing adherence.

Research Evidence / Overview of Studies for Lactafem

---

Evidence for use in Type 2 Diabetes Mellitus

Research examined Lactafem in studies involving conditions characterized by systemic or functional imbalance, such as Type 2 Diabetes Mellitus, primarily utilizing short-term, randomized controlled trials. The outcomes studied related to physiological strain, including measurements of long-term blood sugar control, such as glycated hemoglobin (HbA1c), and daily fasting glucose levels. The populations included were generally adults diagnosed with the condition, typically those insufficiently managed by existing therapies, based on trial entry criteria.

Studies reported measurements of observed changes in HbA1c values from baseline. Findings also included reported differences in mean body weight measurements between the study groups. However, evidence remains limited and heterogeneous, and reported outcomes were generally short-term, typically based on follow-up durations that were limited to a few months.

---

Evidence for use in Chronic Weight Management

Lactafem was evaluated in trials where outcomes reflecting daily functioning were monitored in adults presenting with functional limitations due to their body weight. Research examined outcomes related to total body weight and the percentage of weight loss over defined time intervals, with follow-up durations often extending up to approximately 68 weeks. Findings describe patterns observed in the studies related to average reductions in body weight across the observed populations. Data show patterns related to weight change, but the certainty remains low regarding the maintenance of these changes after treatment has stopped. Comparative evidence against other established approaches is limited.

---

What is Still Uncertain About Lactafem

This final section describes the areas where evidence is limited or where certainty remains low. The results apply only to the populations studied, and findings describe group patterns, not personal outcomes for every individual. Specifically, long-term effects are not fully established for many important outcomes, and follow-up durations were limited. Subgroup findings are uncertain, particularly for people with less common complications or certain severe co-existing health issues. This evidence highlights what is known—and what is still uncertain—about this intervention.

Key Studies & References

1. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials
2. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

Common questions about Lactafem (FAQ)

---

Q: How long do common side effects of Lactafem usually last?

Official regulatory information does not specify the exact duration for all common side effects like headache or fatigue. However, for a frequently observed change like bleeding irregularities, the official label notes that this pattern is especially frequent during the first few months of use.

---

Q: Does Lactafem cause changes in appetite or weight gain?

According to official labeling, increased body weight is listed as a very common adverse reaction. The product information does not explicitly list changes in appetite within the most frequent categories of side effects.

---

Q: Are there any specific foods that should be avoided when using Lactafem?

Official regulatory documents generally state that Lactafem can be taken with or without food. There are no specific common foods documented in the product's official labeling that are required to be avoided due to a known interaction.

---

Q: Are there any restrictions on Lactafem use for people with kidney or liver issues, based on official labels?

Lactafem is strictly contraindicated (must not be used) if an individual has severe hepatic disease until liver function has fully normalized. Official documents do not specify any dose adjustments for patients with renal (kidney) impairment.

---

Q: Was Lactafem tested in clinical trials involving a large number of people?

Official regulatory documents detail the randomized controlled trials that provided the evidence for the drug's approval. The resulting information and findings are based on the patterns and data collected from the patient populations studied in these clinical trials.

---

Q: How is the active ingredient in Lactafem processed or metabolized by the body?

The active ingredient, desogestrel, is quickly absorbed and then needs to be processed by the body. This metabolism converts desogestrel into its potent active metabolite, etonogestrel, which is necessary for the drug’s action.

---

Q: Does Lactafem affect the levels of any hormones in the body?

As a synthetic progestin-only medicine, Lactafem's core purpose is to interrupt the process of conception. Its effect relies on the synthetic hormone component to cause inhibition of ovulation and physically alter the cervical mucus.

---

Q: Can Lactafem affect the results of common lab tests like blood counts or liver function?

Official labeling notes that the use of hormonal contraceptives may influence the results of some laboratory tests. These tests may include parameters related to hepatic (liver) function, thyroid function, and blood coagulation.

---

Q: Is it true that Lactafem is a 'pro-drug' that requires activation by the body?

The regulatory information indicates that the original compound, desogestrel, is converted into its active metabolite, etonogestrel, in the body. This conversion process is necessary for the substance to become effective.

---

Q: How does the body naturally eliminate Lactafem? (Elimination/pharmacokinetics)

After the active substance is metabolized by the body, it is naturally eliminated. The active substance and its metabolites are excreted mainly via the urine and, to a lesser extent, via the faeces (feces).

---

Q: Is Lactafem known to cause headaches or migraines?

Official labeling lists headache as a very common adverse reaction. The safety profile also notes the potential for migraines as a condition that may require evaluation or monitoring.

---

Q: What is the shelf life of Lactafem tablets or capsules?

The specific shelf life (e.g., in months or years) for the product is formally documented in the official regulatory labeling (SmPC) under the section addressing expiry. The official labeling indicates that the product should not be used past the expiration date printed on the packaging.

---

Q: Is Lactafem a controlled substance?

The drug is consistently classified as a prescription-only medicine by regulatory bodies. The designation as a controlled substance is managed separately by specific governing bodies and can vary depending on the country.

---

Q: Can Lactafem affect sleep patterns?

The official safety profile lists fatigue and headache as common reactions. While sleep disturbances, such as insomnia, are not explicitly noted in the most common side effect categories, the label does not exclude all related effects.

---

Q: Does Lactafem interact with alcoholic beverages?

Official regulatory information does not include a specific warning or instruction against the consumption of alcoholic beverages while using this medicine.

---

Q: Is it safe to drink coffee or caffeine while taking Lactafem?

There are no specific warnings or documented interactions in the official labeling related to the use of caffeine or coffee during Lactafem use.

---

Q: Does Lactafem interact with common vitamins like Vitamin D or B12?

The official product labeling does not list documented interactions with common vitamins such as Vitamin D or Vitamin B12.

---

Q: What types of over-the-counter pain relievers are documented to interact with Lactafem?

Regulatory documents do not list specific interactions with common over-the-counter pain relievers, such as paracetamol or ibuprofen, that require special warnings.

---

Q: How quickly can a person expect Lactafem to start working? (Onset)

Official regulatory documents specify the appropriate time (e.g., related to the first day of the menstrual cycle, or time after starting) for contraceptive protection to become effective.

---

Q: Does Lactafem carry warnings for people with pre-existing heart conditions?

Official labeling notes the potential increased risk of venous thromboembolism (VTE), which is a circulatory condition. The product is strictly contraindicated (must not be used) in individuals with a history of VTE.

---

Q: Can people with known allergies to certain drug classes use Lactafem?

The drug is contraindicated (must not be used) for any individual with a known hypersensitivity or allergy to the active substance (Desogestrel) or any of the inactive ingredients (excipients) used in the product.

---

Q: Can a person become physically dependent on Lactafem?

Official regulatory documents do not mention or document physical dependence, misuse, or abuse potential associated with the use of this medicine.

---

Q: What does the regulatory label say about driving or operating machinery while taking Lactafem?

Official regulatory information states that the medicine is considered to have no or negligible influence on the ability to drive and use machines.

---

Q: Why is Lactafem available only by prescription?

The drug is classified as a prescription-only medicine. This regulatory decision is based on its class (a hormonal contraceptive) and the requirement for patient evaluation and medical oversight prior to use.

---

Q: Does Lactafem contain common allergens like gluten or lactose?

Official labeling lists the inactive ingredients (excipients) and typically notes the presence of common substances such as lactose where applicable. This information is included in the labeling for patient review.

---

Q: Can Lactafem cause issues with vision or eyes?

Official safety profiles sometimes note vision or eye-related effects, such as intolerance to contact lenses, which may be related to fluid changes. The official safety information notes these potential effects.

How to Store and Dispose of Lactafem?

This information is based strictly on regulatory labeling requirements.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (e.g., 20 C to 25 C).
Handling	Do not freeze and avoid excessive heat. Protect the medicine from moisture and light.
Packaging	Keep out of reach of children. Keep the product in its original, tightly closed container until the expiration date.

Disposal Instructions

To dispose of unused or expired Lactafem, follow official government guidelines to maintain public and environmental safety. Do not dispose of the medication by pouring it down a drain or flushing it down a toilet unless explicitly instructed by the label. The product should typically be taken to a drug take-back program or disposed of according to the official household trash preparation rules established by local regulatory authorities.